Ozempic and Wegovy: How 2 diabetes medications became the most popular weight-loss drugs

Most Innovative Companies

コンテンツは Mansueto Ventures and Fast Company によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、Mansueto Ventures and Fast Company またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

10M ago 57:14

MP3•エピソードのホーム

In the United States, nearly three-quarters of adults qualify as overweight or obese, 42% of whom are considered obese. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035.

‘Fast Company’ contributing writer Adam Bluestein joined us to break down how Novo Nordisk, the company behind Ozempic and Wegovy, developed and marketed its weight-loss drugs. He also explained why the drugs have become so popular in the U.S., how drug pricing is extremely complicated and . . . how the medications actually work to help people lose weight.

Also, we chatted with Trina Spear about how she founded Figs, a DTC healthcare apparel company.

112 つのエピソード

#Tech #Business #Mansueto Ventures #Fast Company #MBA